A practical view on MDR and its challenges
Since the introduction of MDR (EU) 2017/745, many manufacturers describe the regulation as demanding and time-intensive. And while MDR is thorough by design, many of the hurdles companies face stem from fragmented processes rather than the regulation itself.
Where challenges often arise
We regularly see organizations struggle when:
- MDR becomes a documentation task instead of a structured system aligned with Annex II and III.
- Clinical evaluation is added too late, leaving Article 61 and Annex XIV disconnected from early development steps.
- Risk management runs on a separate track, meaning ISO 14971 is not fully embedded throughout the lifecycle.
- The regulatory pathway isn’t defined early, creating uncertainty from classification (Annex VIII) to the appropriate conformity assessment route (Annex IX/X/XI).
A timely point: legacy device transition
Under MDR Article 120, the transition period for legacy devices is entering its final phase. This means:
- Directive certificates will expire
- MDR compliance becomes essential for continued market access
- Notified Body capacity and timelines will play an even more critical role
The good news
When approached as an integrated process, MDR becomes far more predictable. Organizations that move efficiently tend to:
Define a regulatory strategy at an early stage
Align clinical, quality, and regulatory functions
Build documentation into their daily processes
MDR is more than a regulatory requirement because it’s a framework designed to ensure safety, performance, and long-term product reliability. The key difference lies not in the regulation itself, but in how it is implemented.
Contact us!
Would you like to have more information on our MDR service? Fill out the form to contact our experts.